Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma.

Various drugs have been associated with the development of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Among the biologic agents, alpha-interferon therapy, used for treatment of hepatitis B and chronic myelogenous leukemia, has been associated with TTP in a few recent reports. The authors report the first case of TTP/HUS occurring in a metastatic melanoma patient receiving treatment with high-dose interleukin-2 (IL-2). A 57-year-old patient with malignant melanoma presented with seizures 3 days after completing the first week of high-dose IL-2, and the characteristic hematologic picture revealed TTP/HUS. This occurrence is unlikely to be explained by the association with malignant melanoma, which was not presenting with widespread visceral disease at the time of the occurrence, or by the use of other medications. Similar cytokine release profiles are encountered in TTP, HUS caused by Shiga toxin-1, HUS caused by E. coli O157, after IL-2 or IL-2-containing biochemotherapy, as well as in TTP caused by interferon-alpha. This cytokine profile could reflect a common cause, or just the presence of similar pathways involved.

[1]  S. Swisher,et al.  Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: Correlation with clinical toxicity , 2005, Cancer Immunology, Immunotherapy.

[2]  F. Giles,et al.  Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias , 2005, Cancer Immunology, Immunotherapy.

[3]  D. Newburg,et al.  Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. , 2004, Microbial pathogenesis.

[4]  J. Rand,et al.  Controversies in differentiating thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. , 2003, The Mount Sinai journal of medicine, New York.

[5]  M. Minden,et al.  Vascular Events Associated with Alpha Interferon Therapy , 2003, Leukemia & lymphoma.

[6]  G. Choquet-Kastylevsky,et al.  Adverse effects of immunotherapeutics involving the immune system. , 2002, Toxicology.

[7]  P. Raanani,et al.  Immune-Mediated Complications during Interferon Therapy in Hematological Patients , 2002, Acta Haematologica.

[8]  T. Pysher,et al.  Response to Shiga Toxin-1, with and without Lipopolysaccharide, in a Primate Model of Hemolytic Uremic Syndrome , 2001, American Journal of Nephrology.

[9]  J. Lee,et al.  Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  T. Honda,et al.  Increased Serum IL-10 and Endothelin Levels in Hemolytic Uremic Syndrome Caused by Escherichia coli O157 , 2000, Nephron.

[11]  B. Dreyfus,et al.  Thrombotic Thrombocytopenic Purpura during Interferon Alpha Treatment for Chronic Myelogenous Leukemia , 1999, Acta Haematologica.

[12]  H. Kantarjian,et al.  Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia , 1999, Cancer.

[13]  O. Wagner,et al.  Activation of endothelium by immunotherapy with interleukin‐2 in patients with malignant disorders , 1999, British journal of haematology.

[14]  T. Michida,et al.  Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C , 1998, Journal of Gastroenterology.

[15]  Taylor Jl,et al.  The effects of interferon-alpha on the production and action of other cytokines. , 1998 .

[16]  Yang Wang,et al.  Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. , 1998, The Journal of clinical investigation.

[17]  J. Dutcher,et al.  Fulminant metastatic melanoma complicated by a microangiopathic hemolytic anemia. , 1998, Hematopathology and molecular hematology.

[18]  M. Ravid,et al.  Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients. , 1998, Acta haematologica.

[19]  S. Grossberg,et al.  The effects of interferon-alpha on the production and action of other cytokines. , 1998, Seminars in oncology.

[20]  M. Lee,et al.  Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy. , 1996, The Western journal of medicine.

[21]  J. Baars,et al.  The release of interleukin-8 during intravenous bolus treatment with interleukin-2. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  H. Wada,et al.  Plasma cytokine levels in thrombotic thrombocytopenic purpura , 1992, American journal of hematology.

[23]  S. Swisher,et al.  Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. , 1991, Cancer immunology, immunotherapy : CII.

[24]  H. Prydz,et al.  Cytokine-induced procoagulant activity in monocytes and endothelial cells. Further enhancement by cyclosporine. , 1988, Transplantation.

[25]  A. Murgo.  Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. , 1987, Seminars in hematology.

[26]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[27]  A. Santoro,et al.  [Thrombotic thrombocytopenic purpura due to administration of Ibuprofen]. , 1974, Minerva nefrologica.